Abbonarsi

Patient dosimetry during coronary interventions: a comprehensive analysis - 26/08/11

Doi : 10.1016/j.ahj.2003.04.001 
Efstathios P Efstathopoulos, PhD a, b, Evangelia Karvouni, MD, PhD a, Sofia Kottou, PhD c, Efthalia Tzanalaridou, BSc a, Socrates Korovesis, MD a, Eleftherios Giazitzoglou, MD a, Demosthenes G Katritsis, MD, PhD a,
a Department of Cardiology, Athens Euroclinic, Athens, Greece 
b Second Department of Radiology, University of Athens, Athens, Greece 
c Department of Medical Physics, University of Athens, Athens, Greece 

*Reprint requests: Demosthenes Katritsis, MD, PhD, Director, Department of Cardiology, Athens Euroclinic, 9 Athanasiadou Str., 115 21 Athens, Greece.

Abstract

Background

We performed a detailed analysis of patient radiation during coronary interventions, comparing dose measurements to established dose reference levels, assessing coronary artery doses, and estimating total radiation risk of fatal cancer.

Methods

We prospectively examined 281 patients who were subjected to 307 percutaneous coronary interventions.

Results

The mean kerma area product (KAP) per procedure was 82.1 ± 47.9 Gy.cm2. Corresponding values for fluoroscopy and digital cineangiography were 28.3 ± 25.5 Gy.cm2 and 53.8 ± 35.5 Gy.cm2, respectively, and exposure times were 13.1 ± 6.8 minutes (87%) and 2.0 ± 1.5 minutes (13%), respectively. The right anterior oblique caudal and left anterior oblique cranial projections accounted for the highest amount of KAP (24.0% and 23.1%, respectively) compared with other projections. The maximum recorded skin-dose was 182 mGy. Performing a representative procedure on a phantom, the effective dose was 14.9 mSv. The mean coronary dose was 61.7 ± 38.2 mGy, with a highest calculated dose of 220.1 mGy. The third quartile of KAP measurements was 105 Gy.cm2, the 95th percentile was 175 Gy.cm2, and the mean value of KAP measurements was 82 Gy.cm2. The total risk for the development of fatal cancer was calculated as 83 cases for every 100,000 patients subjected to coronary intervention.

Conclusions

A detailed analysis of patient radiation during coronary interventions is presented. Coronary doses and total radiation risk of fatal cancer are also calculated, and a method for establishing dose reference level values is proposed.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Supported in part by the European Commission's Radiation Protection Research Program DIMOND III (Measures for Optimising Radiological Information and Dose in Digital Imaging and Interventional Radiology; contract number: FIGM CT2000-00061).


© 2004  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 147 - N° 3

P. 468-475 - Marzo 2004 Ritorno al numero
Articolo precedente Articolo precedente
  • Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation
  • James L Orford, Panayotis Fasseas, Steven Melby, Kelli Burger, Steven R Steinhubl, David R Holmes, Peter B Berger
| Articolo seguente Articolo seguente
  • Frequency and time course of reocclusion and restenosis in coronary artery occlusions after balloon angioplasty versus wiktor stent implantation: results from the Mayo-Japan Investigation for Chronic Total Occlusion (MAJIC) Trial
  • Hideo Tamai, Peter B Berger, Etsuo Tsuchikane, Takahiko Suzuki, Hideo Nishikawa, Tadanori Aizawa, Kenshi Fujii, Youichi Nozaki, Eisho Kyo, Toru Kobayashi, Johan Reiber, Anton W.M Van Weert, MAJIC Investigators

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.